EXEL - EXELIXIS Weekly Chart - a difficult stock to pronounce correctly, but despite that it’s new all time highs today for the molecule therapy drug developer. This biotech has seen the last 4 quarters with close to 500% growth in sales, a key characteristic in big winning stocks.
see more biotech stock analysis: http://tradingroom.tech/biotechs-analysis/